PMID- 38260136 OWN - NLM STAT- MEDLINE DCOM- 20240124 LR - 20240304 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3. PG - 1285529 LID - 10.3389/fendo.2023.1285529 [doi] LID - 1285529 AB - INTRODUCTION: Neuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neuroendocrine neoplasms. In contrast to NET G1 and G2 as well as neuroendocrine carcinomas (NEC), in NET G3 data on treatment and patient outcomes are still limited. Especially in a metastasized tumor stage, the role of surgery, peptide receptor radionucleotide therapy (PRRT), and systemic chemotherapy is not clearly defined. METHODS: In this real-life cohort, we consecutively analyzed clinical outcome in NET G3 patients receiving different diagnostic and treatment. RESULTS AND DISCUSSION: We found that even metastasized NET G3 patients undergoing surgery, or receiving radiation, somatostatin analogues (SSA), and PRRT showed a clear survival benefit. Interestingly, all treatment regimen were superior to classical chemotherapeutic agents. In addition, somatostatin receptor (SSTR) PET-CT, FDG PET-CT, and repetitive biopsies were shown to be useful diagnostic and prognostic tools in NET G3. Our study demonstrates that patients with highly proliferative NET G3 might benefit from less aggressive treatment modalities commonly used in low proliferative NEN. CI - Copyright (c) 2024 Hinterleitner, Pfeiffer, Trautwein, Sipos, Singer, Nadalin, Konigsrainer, Lauer, la Fougere, Zender and Hinterleitner. FAU - Hinterleitner, Martina AU - Hinterleitner M AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. FAU - Pfeiffer, Ruben AU - Pfeiffer R AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. FAU - Trautwein, Nils F AU - Trautwein NF AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany. FAU - Sipos, Bence AU - Sipos B AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. FAU - Singer, Stephan AU - Singer S AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - Department of Pathology, University Hospital Tuebingen, Tuebingen, Germany. FAU - Nadalin, Silvio AU - Nadalin S AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - Department of General and Transplant Surgery, University Hospital Tuebingen, Tuebingen, Germany. FAU - Konigsrainer, Alfred AU - Konigsrainer A AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - Department of General and Transplant Surgery, University Hospital Tuebingen, Tuebingen, Germany. FAU - Lauer, Ulrich M AU - Lauer UM AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. AD - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, Germany. FAU - la Fougere, Christian AU - la Fougere C AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. AD - Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany. AD - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, Germany. FAU - Zender, Lars AU - Zender L AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. AD - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tuebingen, Germany. FAU - Hinterleitner, Clemens AU - Hinterleitner C AD - Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany. AD - European Neuroendocrine Tumor Society (ENETS) Center of Excellence, University Hospital Tuebingen, Tuebingen, Germany. AD - German Research Foundation Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Tuebingen, Germany. AD - Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240108 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM MH - Humans MH - *Neuroendocrine Tumors/therapy MH - Positron Emission Tomography Computed Tomography MH - *Carcinoma, Neuroendocrine MH - Aggression MH - Biopsy PMC - PMC10800837 OTO - NOTNLM OT - G3 OT - PET OT - grading OT - neuroendocrine tumor OT - somatostatin receptor OT - treatment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/01/23 12:42 MHDA- 2024/01/24 06:42 PMCR- 2023/01/01 CRDT- 2024/01/23 10:34 PHST- 2023/09/03 00:00 [received] PHST- 2023/12/06 00:00 [accepted] PHST- 2024/01/24 06:42 [medline] PHST- 2024/01/23 12:42 [pubmed] PHST- 2024/01/23 10:34 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1285529 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2024 Jan 8;14:1285529. doi: 10.3389/fendo.2023.1285529. eCollection 2023.